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Pyruvate kinase (PK) deficiency is the most common red cell glycolytic enzyme defect causing 
hereditary non-spherocytic hemolytic anemia.  Current treatments are mainly supportive and 
include red cell transfusions and splenectomy.11  Regular red cell transfusions are known to 
result in iron overload; however, the prevalence and spectrum of transfusion-independent iron 
overload in the overall PK deficient population has not been well defined. This analysis 
describes the prevalence and clinical characteristics of iron overload in patients enrolled in the 
PK Deficiency Natural History Study (NHS) with a focus on those patients who are not regularly 
transfused.2 
 
The PK deficiency NHS protocol (NCT02053480) was approved by each site’s Institutional 
Review Board and/or Ethics Committee, and study procedures were in accordance with the 
Helsinki declaration.  In Lancaster, Pennsylvania, in which all enrolled patients are Amish, 
additional laboratory and radiologic data were collected under a site-specific IRB-approved 
protocol.  All patients gave informed consent. The NHS enrolled 278 patients with PK deficiency 
from June 2014 through April 2017 at 31 centers in 6 countries.  A detailed description of the 
cohort is published elsewhere.2  Twenty-four patients were excluded due to the inability to 
confirm two pathogenic PKLR mutations.  Patients less than one year old at enrollment were 
also excluded (n=12) from this analysis, because ferritin is less reliably related to iron overload 
in this youngest age group, leaving 242 participants reported herein. Patients were defined as 
regularly transfused if they had received ≥6 transfusions in the 12 months prior to enrollment.  
At enrollment, 82% (198/242) of patients were not receiving regular transfusions; 38% (53/138) 
of these patients had iron overload as defined by ferritin.  The patients with iron overload were 
older, more anemic, and more often splenectomized, and had a higher median total bilirubin 
(Table 1).   
 
Baseline and retrospective clinically available data were used.  Serum ferritin levels and 
quantitative (T2*) liver and heart MRIs were used to assess iron overload.  Patients were 
considered to have iron overload if (i) their highest ferritin was over 1000 ng/ml, or (ii) they 
received chelation therapy in the 12 months prior to enrollment, or (iii) their highest liver iron 
concentration (LIC) was >3 mg/g dry weight liver (DW) on T2* MRI, OR (iv) they had cardiac 
iron overload as defined by a cardiac T2* ≤20ms at any time in their history.  The definition of 
iron overload as an LIC >3 mg/g DW was based on guidelines for β-thalassemia.3, 4   
 
Baseline characteristics and results are listed in Table 1. Of the 242 patients, 175 (72%) had 
ferritin levels measured within the prior 12 months. The median ferritin was 583 ng/ml (range: 
17-5630 ng/ml). The overall prevalence of iron overload as defined by ferritin or chelation was 
45% (82/181).  Patients without ferritin monitoring had fewer transfusions (1% vs 25% regularly 
transfused, p<0.0001) and a higher hemoglobin (Hb) level (median Hb 9.6 vs. 8.8 g/dl, p=0.01, 
Supplemental Table 1).  
 
An MRI for liver iron assessment was conducted in 65 (27%) patients in the 12 months prior to 
enrollment; 47 (72%) were from the Amish cohort and obtained per protocol.  Of the patients 
who were not receiving regular transfusions that had MRI or chelation data available, 82% 
(67/82) had iron overload as defined by MRI or chelation (Table 1).  Of those patients who had 
never been transfused and had MRI or chelation data available, 6 of 7 patients met criteria for 
iron overload (6/7 splenectomized).   
 
MRI for cardiac iron assessment was available for 75 (31%) patients.  Five patients (7%) had 
cardiac iron overload; only one of these patients had LIC measured (5 mg Fe/g DW).  These 
patients’ ages ranged from 3-34 years with a median number of lifetime transfusions of 39 
(range 10-90). 
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There were 68 patients ages 1-<10 years old.  Of those who were not regularly transfused at 
enrollment but had received occasional transfusions, 82% (9/11) had iron overload as defined 
by MRI.  The median number of lifetime transfusions in this group was 22.5 (range: 11-85).  Of 
those <10 years old who had never been transfused (n=9), MRI was available for only one 
patient, which confirmed iron overload.   
 
Forty-five patients had paired ferritin and LIC measurements available (Figure 1).  Using a 
ferritin cut off of 1000 ng/ml, the sensitivity to predict LIC >3 mg/g DW was 53% and the 
specificity was 100%.  At a ferritin cut-off of 500 ng/ml, the sensitivity for LIC >3 mg/g DW was 
90% and the specificity was 67%.   
 
Of the 242 patients, 82 (34%) had been prescribed chelation therapy during their lifetime.  The 
median age at the time chelation therapy was first initiated was 10.4 years (range: 0.7-47.9 
years).  Of those who had never been transfused, 10% had received chelation therapy.  Of 
those patients ages 1-<10 years at enrollment, 19% had been on chelation therapy starting at a 
median age of 2.4 years (range: 2-5 years).   
 
Disease treatment of Amish patients differed significantly from the other patients, as these 
patients are typically uninsured and the cost of standard supportive care can be prohibitive. All 
but two Amish patients were splenectomized; none of the splenectomized patients received 
regular transfusions.  Instead of chelation therapy, Amish patients were managed with an iron 
restricted diet and a combination of proton pump inhibitors and calcium citrate to reduce dietary 
iron uptake.  
 
In this PK deficiency Natural History Study, the prevalence of iron overload defined by LIC was 
82% in non-regularly transfused patients.  Although ferritin levels correlated with LIC, ferritin 
levels of >1000 ng/ml had a sensitivity for LIC >3 mg/g DW of only 53%.  A ferritin >1000 ng/ml 
is a conservative threshold for reporting the prevalence of iron overload given the specificity of 
100% but likely underestimates its true prevalence in PK deficiency.  Given that the ferritin >500 
ng/ml had sensitivity of 90%, this is a better cut-off if ferritin is used as a screening test for 
selecting patients for an MRI.   
 
Despite the conservative ferritin threshold of >1000 mg/dl, 38% of all patients who were not 
regularly transfused and 18% of those who were never transfused met this definition of iron 
overload.  Furthermore, 82% of the patients who were not regularly transfused and had an MRI 
or chelation data had a LIC >3 g/mg DW.  These data clearly show that iron overload is not 
limited to regularly transfused patients but is also common in patients who are not regularly 
transfused and even in those who have never been transfused.  This is consistent with the 
findings in thalassemia intermedia in which iron loading occurs both in transfused and non-
transfused patients.5
    
 
There is no consensus definition of when patients with PK deficiency are regarded as regularly 
transfused.  Factors influencing transfusion frequency are often patient or physician dependent. 
Transfusion triggers vary from hospital to hospital and the degree of transfusion dependence of 
the patient might also differ based on characteristics, such as age, growth, and daily activities. 
By choosing a conservatively high cut off of at least 6 transfusions per year to distinguish 
between regularly and not-regularly transfused patients, we minimized the chance of 
confounding transfusion-related iron loading with transfusion independent iron overload.5-7  
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In this study, in non-regularly transfused patients, iron overload had also already occurred at a 
very young age.  In non-regularly transfused patients, an MRI should be considered at the 
earliest age when the procedure can be done without sedation, particularly in patients with 
ferritin levels >500 ng/mL.  In regularly transfused patients, MRI should be considered annually 
after one year of transfusions. 
 
In this cohort, only five patients (7%) had cardiac iron overload by MRI. One patient in the 
cohort developed cardiac iron overload after only 10 lifetime transfusions.  Moreover, the 
youngest patient with cardiac iron overload in this cohort was three years old.  This indicates 
that the number of prior transfusions might not predict which patients are most in need of 
screening for cardiac iron overload.  
 
In the non-Amish cohort, splenectomy was associated with iron loading.  However, this 
association is not clearly causal.  Since splenectomy typically occurs in the more severely 
affected patients with PK deficiency, other factors associated with splenectomy, such as a lower 
hemoglobin or increased transfusion burden, may be contributing to this relationship.  Further 
study is needed to understand whether splenectomy is independently associated with iron 
loading in PK deficiency.  
 
Although the study is biased by its retrospective nature and challenges related to rare disease 
registries, including variability between diagnostic and treatment standards, the results clearly 
show that in PK deficiency, there is a high prevalence of iron overload both in regularly 
transfused and not regularly transfused patients. Ferritin levels below 1000 ng/ml, hemoglobin 
levels above 9 g/dL, young age, and/or an absence of regular transfusions do not exclude the 
possibility of iron overload in patients with PK deficiency. Therefore, iron screening is important 
in all patients with PK deficiency and should be monitored starting in childhood.    Regular 
monitoring for iron overload and treatment, when needed, is imperative to the management of 
this patient population.  
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Table 1. Characteristics of non-regularly transfused patients with PK Deficiency and iron 
overload  
 Ferritin >1000 ng/ml or chelation* LIC >3 mg/g dry weight liver or chelation* 
 Absent  
(85/138, 62%)
 
Present  
(53/138, 38%)
 
p**
 
Absent  
(15/82, 18%) 
Present  
(67/82, 82%) 
p value** 
CHARACTERISTICS    
Female sex 49/85 (58%) 24/53 (45%) 0.2 12/15 (80%) 36/67 (54%) 0.08 
Amish 27/85 (32%) 13/53 (25%) 0.4 14/15 (93%) 33/67 (49%) 0.001 
Age at enrollment (y)    22.6 
(1.6-69.9) 
38.9 
(2.2-60.4) 
0.005 23.4  
(7.4-53.6) 
34.7  
(3.1- 60.4) 
0.3 
Hemoglobin (g/dl)  
 
9.3 
(6.2-14.1) 
8.7 
(6.5-12.0) 
n=52 
0.003 9.9  
(7.6-10.9) 
9.0  
(6.2-12.0) 
n=66 
0.2 
Absolute reticulocyte 
count (106/μL)  
0.2 
(0.1-5.3) 
n=41 
0.5 
(0.1-1.2) 
n=15 
0.2 0.9  
(0.9-1.0) 
n=2 
0.6  
(0.1-0.9) 
n=13 
0.1 
Total Bilirubin (mg/dl)  
 
3.6 
(0.9-9.0) 
n=79 
4.3 
(1.3-17.6) 
n=48 
0.01 3.5  
(1.0-7.2) 
 
3.6  
(1.1-17.6) 
n=62 
0.3 
Ferritin (ng/ml) 
 
388.0 
(31.0-971.5) 
1335.0 
(171.5-5630.0) 
n=47 
ND 362.5 
(126.0-1065.0) 
n=12 
969.0 
(171.5-5630.0) 
n=53 
<0.001 
Liver Iron 
Concentration (LIC, 
mg/g DW) 
 
4.0 
(1.0-8.4) 
n=26 
8.0 
(2.2-33.4) 
n=21 
<0.001 2.0 
(1.0-3.0) 
 
6.4  
(2.2-33.4) 
n=43 
ND 
Transferrin saturation 
(%) 
 
43.3 
(8.8-100.0) 
n=51 
62.0 
(18.4-100.0) 
n=29 
0.02 42.4 
(23.2-96.6) 
 
50.1 
(12.1-100.0) 
n=43 
0.3 
Splenectomized 51/85 (60%) 47/53 (89%) 0.0002 14/15 (93%) 63/67 (94%) 1 
Chelation in prior 12 
months 
0/85 (0%) 31/53 (58%) ND 0/15 (0%) 31/67 (46%) ND 
Never Transfused 18/85 (21%) 4/51 (8%) 0.054 1/15 (7%) 6/65 (9%) 1 
<10 lifetime 
transfusions 
22/61 (36%) 7/39 (18%) 0.07 2/9 (22%) 9/51 (18%) 0.7 
≥10 lifetime 
transfusions 
39/61 (64%) 32/39 (82%) 0.07 7/9 (78%) 42/51 (82%) 0.7 
Numbers are medians (range) or absolute numbers/group total (corresponding percentage). n is 
shown only for those groups that do not contain the total.  *Iron overload by ferritin was defined 
as the number of patients with ferritin>1000 ng/ml or who were treated with chelation therapy in 
the 12 months prior to enrollment.  If a patient had >1 ferritin measurement in the 12 months 
prior to enrollment, the maximum ferritin value was used.  Iron overload based on liver iron 
concentration (LIC) was defined as an LIC >3 mg Fe/g dry weight liver (DW) on T2* MRI in the 
12 months prior to enrollment or who were treated with chelation therapy in the 12 months prior 
to enrollment.  **p values of Fisher’s Exact test or Wilcoxon Rank Sum test. ND: Not Done, 
testing is not appropriate or necessary within the same factor. 
 
8 
 
Figure Legends 
 
 
 
Figure 1 
 
Header: Correlation between ferritin and liver iron concentration (LIC) as measured by MRI 
Legend:  Correlation between ferritin and LIC (r=0.45, p<0.0001, n=45). Gray circles indicate 
the individuals with a median ferritin <1000 ng/mL but a LIC >3 mg/g dry weight liver.  
 
 
 
 

SUPPLEMENTAL TABLE 
Supplemental Table 1:  Patient characteristics, comparing those with iron monitoring to 
those without monitoring, in the 12 months prior to enrollment. 
 Ferritin monitoring 
(n=242) 
MRI monitoring for liver iron 
assessment, in the non-Amish patient 
cohort 
(n=189) 
 Obtained in 
the 12 
months prior 
to enrollment 
(n=175)* 
Not obtained 
in the 12 
months prior 
to enrollment 
(n=67)* 
p-value** Obtained in 
the last 12 
months prior 
to enrollment 
(n=18)* 
Not obtained 
in the last 12 
months prior 
to enrollment 
(n=171)* 
p-value** 
Median*** Age 
at enrollment  
21.8  
(1.3-69.9) 
16.3  
(1.4-60.4) 
0.3 21.1  
(2.2-46.0) 
19.1  
(1.3-69.9) 
0.5 
Transfused in 
the 12 months 
prior to 
enrollment (%) 
72/175 
(41%) 
9/67 
(13%) 
<0.0001 11/18 
(61%) 
67/171 
(39%) 
0.08 
Regularly 
Transfused (%) 
43/175 
(25%) 
1/67 
(1%) 
<0.0001 7/18 
(39%) 
36/171 
(21%) 
0.1 
Median***  
Hemoglobin 
value (g/dl)  
8.8  
(5.2-14.1) 
n=174 
9.6  
(6.5-13.0) 
n=65 
0.01 8.6  
(6.2-11.1) 
8.7  
(5.2-14.1) 
n=168 
0.3 
Splenectomized 
(%) 
112/175 
(64%) 
37/67 
(55%) 
0.2 15/18 
(83%) 
83/171 
(49%) 
0.006 
*Number of patients with known data (n) are presented in the column headers unless otherwise 
indicated in the table. **Using Fisher’s exact test for categorical variables and Wilcoxon rank-
sum test for continuous variables.  ***Median presented with ranges. 
